Fri, Nov 28, 2014, 8:49 PM EST - U.S. Markets closed early today

Recent

% | $
Quotes you view appear here for quick access.

CorMedix, Inc. Message Board

  • steve.higgins16 steve.higgins16 Jan 8, 2014 5:45 PM Flag

    Prosl Patent

    Mark, the patent is granted it is on page 630 of the EPO bulletin.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • For months, this board has presumed that CRMD would sue TP to protect a patent position that would insure a large market share for CRMD in Europe. Management said they are not going to pursue that. Some are saying that the patent only applies to oncology. I am not currently holding a position, but my current opinion is that this misunderstnading between investors and management is sketchy to say the least. If there is no IP position then I would think the team would be clear about that when they see that coming out in due diligence pieces. If there is an IP position there is no question IMHO that the fiduciary responsibility of management to shareholders is to protect the position. What's the situation here?

    • Steve,
      Thanks!
      -Biotech77030

      From Page 630 of the Europen Patent Bulletin - January 8, 2014...

      (A61M) II.1(1)
      Europäisches Patentblatt
      European Patent Bulletin
      Bulletin européen des brevets
      Patente
      Patents
      Brevets (02/2014) 08.01.2014
      -------------------------------------------------------------------------
      (51) A61M 25/00 (11) 1 814 562 B1
      A61K 31/18 A61K 31/185
      A61K 31/727
      (25) En (26) En
      (21) 05803391.1 (22) 12.10.2005
      (84) AT BE BG CH CY CZ DE DK EE ES FI FR GB
      GR HU IE IS IT LI LT LU LV MC NL PL PT
      RO SE SI SK TR
      (43) 08.08.2007
      (86) US 2005/036451 12.10.2005
      (87) WO 2006/049813 2006/19 11.05.2006
      (30) 02.11.2004 US 979547
      (54) • ANTIMIKROBIELLE LÖSUNGEN AUS
      TAURINAMID-DERIVATEN UND BIOLOGISCH
      VERTRÄGLICHEN SALZEN UND
      SÄUREN UNTER ZUGABE VON GERINGEN
      HEPARIN-KONZENTRATIONEN
      • ANTIMICROBIAL LOCKING SOLUTIONS
      COMPRISING TAURINAMIDE DERIVATIVES
      AND BIOLOGICALLY
      ACCEPTABLE SALTS AND ACIDS, WITH
      THE ADDITION OF SMALL CONCENTRATIONS
      OF HEPARIN
      • SOLUTIONS DE BLOCAGE ANTI-MICROBIEN
      COMPRENANT DES DERIVES DE
      TAURINAMIDE AINSI QUE DES SELS ET
      DES ACIDES BIOLOGIQUEMENT ACCEPTABLES,
      AVEC ADJONCTION D'HEPARINE
      EN FAIBLES CONCENTRATIONS
      (73) ND Partners, LLC., One Joy Street, Boston,
      MA 02108, US
      (72) PROSL, Frank, R., Druxbury, MA 02232, US
      (74) Ede, Eric, et al, Murgitroyd & Company
      Scotland House 165-169 Scotland Street,
      Glasgow G5 8PL, GB

      • 1 Reply to biotech77030
      • Hopefully we see some PR soon to confirm the issuance. The interesting part is how will TP respond (if at all) . TP has always assumed CRMD would run out of cash. Yesterday's raise smites this assumption since CRMD now has enough liquidity to both fund operations AND initiate legal action. Hats off to the team----they raised the money will no Wall Street sponsorship. Imagine what would happen if we ever get a following even amongst the smaller institutions.
        Valuation here is compelling. In months CRMD could potentially be running a PHIII trial in the States with a large partner. What is the value of an approved product in EU and a relatively short approval pathway in the U.S.??? I would argue today's valuation does not even come close.

 
CRMD
1.3999-0.0801(-5.41%)Nov 28 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Energy XXI Ltd.
NasdaqGSFri, Nov 28, 2014 1:00 PM EST
EOG Resources, Inc.
NYSEFri, Nov 28, 2014 1:01 PM EST